Brooks Laboratories Limited (NSE:BROOKS)

Market Cap	1.40B -65.3%
Revenue (ttm)	888.46M +15.4%
Net Income	216.03M
EPS	7.40
Shares Out	29.46M
PE Ratio	6.41
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	119,127
Average Volume	106,265
Open	49.48
Previous Close	49.93
Day's Range	47.44 - 49.48
52-Week Range	36.30 - 164.02
Beta	1.10
RSI	32.47
Earnings Date	May 18, 2026

About Brooks Laboratories

Brooks Laboratories Limited provides contract development and manufacturing services for pharmaceutical companies in India and internationally. The company’s product portfolio includes liquid injection ampoules and vials, dry powder injection vials, lyophilized injections, eye/ear drops, and nasal drops; B-Lactam and cephalosporin tablets, dry powder syrups, and injections; general, liquid, and dry powder injections; formulations for antibiotics, pain management, and controlled drugs; and oncology products and hormonal injections, etc. It also ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2002
• Employees: 323
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BROOKS

Financial Performance

In fiscal year 2025, Brooks Laboratories's revenue was 825.57 million, an increase of 3.86% compared to the previous year's 794.86 million. Losses were -99.67 million, -49.13% less than in 2024.